Facing the challenges of the next generation exascale computing,National University of Defense Technology has developed a prototype system to explore opportunities,solutions,and limits toward the next generation Tianh...Facing the challenges of the next generation exascale computing,National University of Defense Technology has developed a prototype system to explore opportunities,solutions,and limits toward the next generation Tianhe system.This paper briefly introduces the prototype system,which is deployed at the National Supercomputer Center in Tianjin and has a theoretical peak performance of 3.15 Pflops.A total of 512 compute nodes are found where each node has three proprietary CPUs called Matrix-2000+.The system memory is 98.3 TB,and the storage is 1.4 PB in total.展开更多
Environmental and food safety concerns over transgenic plants have hampered commercial applications of transgenic plant technology worldwide. A recently developed transgene deletion technology, named gene deletor tech...Environmental and food safety concerns over transgenic plants have hampered commercial applications of transgenic plant technology worldwide. A recently developed transgene deletion technology, named gene deletor technology, may be used to eliminate all transgenes from pollen, seeds, fruits or other organs when functions of transgenes are no longer needed or their presence may cause concerns. In this review, I will briefly describe the principle of the gene deletor technology with major supporting experimental data. I will also explain main characteristics and requirements of the gene deletor technology. Finally, I will discuss the gene deletor technology in the context of how it may be used to alleviate environmental and food safety concerns over transgenic plants in vegetatively and sexually propagated plants, to prevent volunteer transgenic plants, to protect proprietary transgenic technologies, and to allow farmers to reuse their harvested seeds for future planting.展开更多
Near-infrared (NIR) spectroscopy was applied to reagent-free quantitative analysis of polysaccharide of a brand product of proprietary Chinese medicine (PCM) oral solution samples. A novel method, called absorbance up...Near-infrared (NIR) spectroscopy was applied to reagent-free quantitative analysis of polysaccharide of a brand product of proprietary Chinese medicine (PCM) oral solution samples. A novel method, called absorbance upper optimization partial least squares (AUO-PLS), was proposed and successfully applied to the wavelength selection. Based on varied partitioning of the calibration and prediction sample sets, the parameter optimization was performed to achieve stability. On the basis of the AUO-PLS method, the selected upper bound of appropriate absorbance was 1.53 and the corresponding wavebands combination was 400 - 1880 & 2088 - 2346 nm. With the use of random validation samples excluded from the modeling process, the root-mean-square error and correlation coefficient of prediction for polysaccharide were 27.09 mg·L<sup>-</sup><sup>1</sup> and 0.888, respectively. The results indicate that the NIR prediction values are close to those of the measured values. NIR spectroscopy combined with AUO-PLS method provided a promising tool for quantification of the polysaccharide for PCM oral solution and this technique is rapid and simple when compared with conventional methods.展开更多
Acute myocardial infarction(AMI)is associated with a challenging prognosis.Notably,the Tongxinluo capsule(TXL),a proprietary Chinese medicine,has garnered attention for its potential therapeutic effects.This study aim...Acute myocardial infarction(AMI)is associated with a challenging prognosis.Notably,the Tongxinluo capsule(TXL),a proprietary Chinese medicine,has garnered attention for its potential therapeutic effects.This study aimed to elucidate the concealed pharmacological benefits of TXL in AMI patients and identify pertinent immunological targets.In the GSE66360 dataset,172 upregulated genes and 16 downregulated genes were discerned.Subsequently,803 key targets of TXL were meticulously sifted through the Traditional Chinese Medicine Systems Pharmacology(TCMSP)and Herbal Ingredients’Targets(HERB)databases.The intersection of these datasets was determined using Venn diagrams.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses unveiled that these genes were predominantly associated with the NF-kappa B signaling pathway,TNF signaling pathway,IL-17 signaling pathway,and other signaling cascades.The extent of immune infiltration between AMI and control samples was assessed using Cibersort,and Spearman’s rank correlation was employed to explore the relationship between immune cells and the amalgamated genes.This investigation revealed that the amelioration of AMI with TXL might be linked to an augmentation in mast cell-activated cells and neutrophil invasion.The Weighted Gene Co-expression Network Analysis(WGCNA)identified gene modules strongly correlated with 22 immune cells.These modules were further scrutinized using the Cibersort algorithm,leading to the recognition of eight genes deemed pivotal as potential novel molecular markers for TXL treatment of AMI.The infiltration of defense cells was also found to exert a significant impact.This study contributed to our understanding of the pharmacological mechanisms of TXL and provided valuable insights for future investigations into potential targets for AMI immunotherapy.展开更多
Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease,has a high global prevalence and can progress to metabolic dysfunction-associated steatohepatitis,cir...Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease,has a high global prevalence and can progress to metabolic dysfunction-associated steatohepatitis,cirrhosis,and hepatocellular carcinoma.The pathogenesis of MASLD is primarily driven by disturbances in hepatic lipid metabolism,involving six key processes:increased hepatic fatty acid uptake,enhanced fatty acid synthesis,reduced oxidative degradation of fatty acids,increased cholesterol uptake,elevated cholesterol synthesis,and increased bile acid synthesis.Consequently,maintaining hepatic lipid metabolic homeostasis is essential for effective MASLD management.Numerous novel molecules and Chinese proprietary medicines have demonstrated promising therapeutic potential in treating MASLD,primarily by inhibiting lipid synthesis and promoting lipid oxidation.In this review,we summarized recent research on MASLD,elucidated the molecular mechanisms by which lipid metabolism disorders contribute to MASLD pathogenesis,and discussed various lipid metabolism-targeted therapeutic approaches for MASLD.展开更多
In light of the institutional environment transformation and globalisation, this article draws on institutional theory and global value chain theory to explore the growth path of China's state-owned automakers. Th...In light of the institutional environment transformation and globalisation, this article draws on institutional theory and global value chain theory to explore the growth path of China's state-owned automakers. The study finds that the institution and globalisation factors have become the growth driver of state-owned automakers. At each stage, it is found that there is a convergence in the organisational behaviour of state-owned automakers. The change in driving force, has, however, led to the transformation of organisational behaviour of those state-owned automobile enterprises undergoing the process of evolving from a joint venture model to a proprietary innovation model. This change has come about due to the leveraging of partnership opportunities with multinational motor companies.展开更多
Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global ...Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.展开更多
In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly ass...In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. As safety parameters the total number of adverse events, changes in various biochemical and laboratory parameters as well as the global evaluation of tolerability by investigator and subjects compared to placebo were evaluated. RESULTS: In total 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. The tolerability of the arabinogalactan extract was rated as “very good” or “good” by the investigators for 99% of the subjects and by 98% subjects in self-assessment with no statistical differences to placebo. CONCLUSION: The measured parameters as well as the evaluation of the tolerability by the investigators and the subjects demonstrate a very good tolerance profile of the proprietary arabinogalactan extract with no differences to placebo when taken for 12 weeks.展开更多
基金supported by the National Key Research and Development Program of China(No.2016YFB0200401)。
文摘Facing the challenges of the next generation exascale computing,National University of Defense Technology has developed a prototype system to explore opportunities,solutions,and limits toward the next generation Tianhe system.This paper briefly introduces the prototype system,which is deployed at the National Supercomputer Center in Tianjin and has a theoretical peak performance of 3.15 Pflops.A total of 512 compute nodes are found where each node has three proprietary CPUs called Matrix-2000+.The system memory is 98.3 TB,and the storage is 1.4 PB in total.
文摘Environmental and food safety concerns over transgenic plants have hampered commercial applications of transgenic plant technology worldwide. A recently developed transgene deletion technology, named gene deletor technology, may be used to eliminate all transgenes from pollen, seeds, fruits or other organs when functions of transgenes are no longer needed or their presence may cause concerns. In this review, I will briefly describe the principle of the gene deletor technology with major supporting experimental data. I will also explain main characteristics and requirements of the gene deletor technology. Finally, I will discuss the gene deletor technology in the context of how it may be used to alleviate environmental and food safety concerns over transgenic plants in vegetatively and sexually propagated plants, to prevent volunteer transgenic plants, to protect proprietary transgenic technologies, and to allow farmers to reuse their harvested seeds for future planting.
文摘Near-infrared (NIR) spectroscopy was applied to reagent-free quantitative analysis of polysaccharide of a brand product of proprietary Chinese medicine (PCM) oral solution samples. A novel method, called absorbance upper optimization partial least squares (AUO-PLS), was proposed and successfully applied to the wavelength selection. Based on varied partitioning of the calibration and prediction sample sets, the parameter optimization was performed to achieve stability. On the basis of the AUO-PLS method, the selected upper bound of appropriate absorbance was 1.53 and the corresponding wavebands combination was 400 - 1880 & 2088 - 2346 nm. With the use of random validation samples excluded from the modeling process, the root-mean-square error and correlation coefficient of prediction for polysaccharide were 27.09 mg·L<sup>-</sup><sup>1</sup> and 0.888, respectively. The results indicate that the NIR prediction values are close to those of the measured values. NIR spectroscopy combined with AUO-PLS method provided a promising tool for quantification of the polysaccharide for PCM oral solution and this technique is rapid and simple when compared with conventional methods.
文摘Acute myocardial infarction(AMI)is associated with a challenging prognosis.Notably,the Tongxinluo capsule(TXL),a proprietary Chinese medicine,has garnered attention for its potential therapeutic effects.This study aimed to elucidate the concealed pharmacological benefits of TXL in AMI patients and identify pertinent immunological targets.In the GSE66360 dataset,172 upregulated genes and 16 downregulated genes were discerned.Subsequently,803 key targets of TXL were meticulously sifted through the Traditional Chinese Medicine Systems Pharmacology(TCMSP)and Herbal Ingredients’Targets(HERB)databases.The intersection of these datasets was determined using Venn diagrams.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses unveiled that these genes were predominantly associated with the NF-kappa B signaling pathway,TNF signaling pathway,IL-17 signaling pathway,and other signaling cascades.The extent of immune infiltration between AMI and control samples was assessed using Cibersort,and Spearman’s rank correlation was employed to explore the relationship between immune cells and the amalgamated genes.This investigation revealed that the amelioration of AMI with TXL might be linked to an augmentation in mast cell-activated cells and neutrophil invasion.The Weighted Gene Co-expression Network Analysis(WGCNA)identified gene modules strongly correlated with 22 immune cells.These modules were further scrutinized using the Cibersort algorithm,leading to the recognition of eight genes deemed pivotal as potential novel molecular markers for TXL treatment of AMI.The infiltration of defense cells was also found to exert a significant impact.This study contributed to our understanding of the pharmacological mechanisms of TXL and provided valuable insights for future investigations into potential targets for AMI immunotherapy.
基金supported by the Research Start-up Funding for the First Affiliated Hospital of USTC(RC2021012)the Fundamental Research Funds for Central Universities(WK9110000004).
文摘Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease,has a high global prevalence and can progress to metabolic dysfunction-associated steatohepatitis,cirrhosis,and hepatocellular carcinoma.The pathogenesis of MASLD is primarily driven by disturbances in hepatic lipid metabolism,involving six key processes:increased hepatic fatty acid uptake,enhanced fatty acid synthesis,reduced oxidative degradation of fatty acids,increased cholesterol uptake,elevated cholesterol synthesis,and increased bile acid synthesis.Consequently,maintaining hepatic lipid metabolic homeostasis is essential for effective MASLD management.Numerous novel molecules and Chinese proprietary medicines have demonstrated promising therapeutic potential in treating MASLD,primarily by inhibiting lipid synthesis and promoting lipid oxidation.In this review,we summarized recent research on MASLD,elucidated the molecular mechanisms by which lipid metabolism disorders contribute to MASLD pathogenesis,and discussed various lipid metabolism-targeted therapeutic approaches for MASLD.
文摘In light of the institutional environment transformation and globalisation, this article draws on institutional theory and global value chain theory to explore the growth path of China's state-owned automakers. The study finds that the institution and globalisation factors have become the growth driver of state-owned automakers. At each stage, it is found that there is a convergence in the organisational behaviour of state-owned automakers. The change in driving force, has, however, led to the transformation of organisational behaviour of those state-owned automobile enterprises undergoing the process of evolving from a joint venture model to a proprietary innovation model. This change has come about due to the leveraging of partnership opportunities with multinational motor companies.
文摘Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.
文摘In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. As safety parameters the total number of adverse events, changes in various biochemical and laboratory parameters as well as the global evaluation of tolerability by investigator and subjects compared to placebo were evaluated. RESULTS: In total 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. The tolerability of the arabinogalactan extract was rated as “very good” or “good” by the investigators for 99% of the subjects and by 98% subjects in self-assessment with no statistical differences to placebo. CONCLUSION: The measured parameters as well as the evaluation of the tolerability by the investigators and the subjects demonstrate a very good tolerance profile of the proprietary arabinogalactan extract with no differences to placebo when taken for 12 weeks.
